PatientsVille.com LogoPatientsVille.com

Female Pattern Hair Loss | Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss

Female Pattern Hair Loss research study

What is the primary objective of this study?

This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.

Who is eligible to participate?

Inclusion Criteria: - Subjects must be premenopausal women older than 18 with female pattern hair loss. Exclusion Criteria: - Androgen excess - Other scalp or hair disorders - Contraindications to spironolactone treatment, especially pregnancy, electrolyte imbalances, history of breast cancer, or intake of interfering drugs - Contraindications to minoxidil treatment, especially patients who are allergic to this treatment or have a history of low blood pressure or irregular heart beats

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Female Pattern Hair Loss

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:SpironolactoneThis study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.

Drug:MinoxidilThis study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Study Status

Completed

Start Date: September 2005

Completed Date: March 9, 2009

Phase: Phase 2

Type: Interventional

Design:

Primary Outcome: hair density

Secondary Outcome: percentage of subjects who experience side effects

Study sponsors, principal investigator, and references

Principal Investigator: Jerry Shapiro, MD

Lead Sponsor: University of British Columbia

Collaborator:

More information:https://clinicaltrials.gov/show/NCT00175617

Discuss Spironolactone